DIASURV^® · MELANOMA

DiaSurv^® brings risk stratificationto early-stage melanoma.

It reads the diagnostic slide to separate higher-risk from lower-risk patients, so care decisions match the patient's actual risk.

RESEARCH USE ONLYNot for use in diagnostic procedures

3,000+patient cases in international research on early-stage melanoma prognosis.

HR 5.03

DiaSurv^® risk score, independent predictor of relapse in multivariable analysis adjusted for AJCC8 stage, Breslow thickness, ulceration, age, sex, site and subtype (p < 0.005).

Kanaan C, et al. ASCO 2025

FROM SLIDE TO REPORT

A risk score from the H&E slide taken at diagnosis,
step by step.

The illustration follows a single slide through tissue detection, tiling and DiaSurv^® analysis, up to the slide-level report.

INPUT

H&E slide

Tissue is detected on the diagnostic slide, fragments are isolated and divided into tiles.

ANALYSIS · MELANOMA

DiaSurv^® reads every tile

The relapse-attention heatmap shows the regions that weigh most on the risk estimate.

REVIEW

Slide-level report

The analysis ends in a slide-level risk report. Research Use Only.

ENDPOINTS

Three endpoints
in the report.

Each endpoint is reported beyond AJCC8 staging. The illustration above shows them at 5 years.

RFS

Recurrence-free survival

Whether the melanoma returns after treatment.

DMFS

Distant metastasis-free survival

Whether the melanoma spreads to distant sites.

Overall survival

How long patients live, whatever the cause.

EVALUATION

See how DiaSurv^® separates high-risk from low-risk melanoma.

The first evaluation follows 540 patients from the IGR melanoma cohort. The second compares DiaSurv^®^* with Gene-Expression Profiling (GEP) in 50 patients. Both are exploratory research analyses.

IGR MELANOMA COHORT · 5 YEARS

Out of 100 High Risk patients, 50 relapsed within 5 years.

Low Risk 7.6% (95% CI 4.7% to 12.2%), High Risk 49.6% (95% CI 43.2% to 56.4%), with Kaplan-Meier curves for both groups over 5 years.

Each dot is one patient out of 100. Percentages are Kaplan–Meier estimates at 5 years, rounded to whole patients. RFS: relapse-free survival. DMFS: distant metastasis-free survival. OS: overall survival. Source: ASCO 2026.

GENE-EXPRESSION PROFILING (GEP) VS DIASURV^®^* · 50 PATIENTS · EXPLORATORY

Which patients did each test flag as High Risk, and who had an event?

Gene-Expression Profiling and DiaSurv compared on 50 patients: number of relapses in each Low Risk and High Risk group, with event curves over 5 years for both tests.

Each dot is one patient. Pink dots had an event during follow-up (median about 5.3 years): 4 relapses and 7 deaths among the 50 patients. With so few events, this analysis is exploratory and cannot show that one test performs better than the other. Curves show the cumulative probability of the event (Kaplan–Meier). Research Use Only. Source: Comparison of an AI-based prognostic assay with gene expression profiling in early-stage melanoma, J Eur Acad Dermatol Venereol.

EVIDENCE

Evidence in melanoma.

View all 12 publications ↗︎

La Presse Médicale · 2026

Artificial Intelligence applied to surgical pathology in the management of cutaneous melanoma

Surgical pathology remains the cornerstone for the diagnosis, staging and prognostic stratification of cutaneous melanoma. The emergence of digital pathology…

Clinical validation of an AI-based prognostic assay for stage I-II cutaneous melanoma

In early-stage cutaneous melanoma (CM), AJCC staging demonstrates limited ability to identify patients at elevated recurrence risk who may benefit from…

Comparison of an AI-based prognostic assay with gene expression profiling in early-stage melanoma

AI-Based Prognostic Assessment Shows Promising Results in Early-Stage Melanoma A recent study published in the Journal of the European Academy of Dermatology…

Discuss your prognosis project.

Start a research conversation ↗︎